Meanwhile, cadonilimab is a bispecific programmed cell death protein-1 (PD-1)/cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody, and it has been shown in clinical investigations that patients with cervical cancer can benefit from cadonilimab monotherapy, regardless of their PD-L1 expression status (7). Here, PDCD1 is linked to cervical carcinoma.